Clinical practice guidelines recommend maintenance with avelumab starting within 10 weeks of competition of cisplatin-based regimens in patients without progression of metastatic bladder cancer with combination chemotherapy. Avelumab plus best supportive care has demonstrated to prolong overall survival compared with best supportive care alone.
In a phase 2 trial, maintenance therapy with the poly ADP ribose polymerase (PARP) inhibitor rucaparib vs placebo was associated with progression-free survival in patients with DNA repair deficiency biomarker-positive metastatic bladder cancer without disease progression after first-line platinum-based chemotherapy.
Systemic immunotherapy is approved for treatment of metastatic bladder cancer in patients who are ineligible for cisplatin-based therapy or in patients with tumors that have relapsed after cisplatin-based therapy.
Learn more about metastatic bladder cancer management.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Kyle A. Richards. Fast Five Quiz: Management of Metastatic Bladder Cancer - Medscape - Jan 30, 2023.